Study design and study assessment
ADVERSE EVENTS
This was a double-blind, randomized, parallel-group, placebo-controlled trial (RCT) to investigate efficacy and safety of varenicline (1 mg, administered twice daily for 12 weeks) versus placebo (administered twice daily, for 12 weeks) together with counseling for vaping cessation in exclusive daily EC users intending to quit vaping.The trial consisted of a 12-week treatment phase directly followed by a 12-week non-treatment phase (Fig. Varevape single — study design. Exclusive daily EC users who intended to quit vaping were randomized to receive either varenicline, 1 mg, twice daily for 12 weeks or matched placebo for 12 weeks. Subjects were prospectively reviewed for up to 24 weeks during which vaping habits, questionnaire answers, adverse events, and vital signs were assessed at each visit. The telephone symbol indicates telephone contact